Home
Drugs
Targets
Pathways
Ontologies
Cyp450s
Adv.search
Help/FAQ

Drug-Target Interaction

Drug

show drug details
PubChem ID:449171
Structure:
Synonyms:
(2E,4E,6Z,8E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-n
(2E,4E,6Z,8E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid
(2E,4E,6Z,8E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)nona-2,4,6,8-tetraenoic acid
(2E,4E,6Z,8E)-3,7-Dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenoic acid
(2E,4E.6Z,8E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexan-1-yl)-2,4,6,8-nonatetraenoic acid
(9cis)-retinoic acid
2,4,6,8-Nonatetraenoic acid, 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-, (2E,4E,6Z,8E)-
5300-03-8
9 Cis Retinoic Acid
9(Z)-Retinoic acid
9-cis RA
9-cis Retinoic Acid
9-cis-RA
9-Cis-Retinoic Acid
9-CIS-RETINOIC ACID (SEE RETINOID PROJECT 6)
9-cis-Tretinoin
9-CRA
9CRA
AGN 192013
AGN-192013
AIDS-060996
AIDS060996
ALITRETINOIN
Alitretinoin (USAN)
Alitretinoin [USAN]
ALRT 1057
ALRT-1057
BAL-4079
BB_NC-1005
BSPBio_001495
C15493
C20H28O2
CCRIS 7098
CHEBI:50648
HSDB 7186
IDI1_033965
LG-100057
LGD 100057
LGD 1057
LGD-1057
LMPR01090022
LS-1328
Mixture Name
NCGC00161590-01
NCGC00161590-02
NCGC00161590-03
NCGC00161590-04
NCGC00161590-05
NCGC00161590-06
NCGC00161590-07
nchembio.106-comp3
nchembio861-comp8
NSC 659772
NSC-659772
NSC659772
PANRETIN
Panretin Gel
Panretyn
Panrexin
R4643_SIGMA
REA
Retinoic acid, 9-cis-
Retinoic acid, cis-9,trans-13-
Ro-04-4079
Spectrum5_001935
STOCK1N-38565
Toctino
UPCMLD-DP097:001
UPCMLD-DP097:002
ATC-Codes:

Target

show target details
Uniprot ID:Q9Y354_HUMAN
Synonyms:
Matrix metalloproteinase 9
EC-Numbers:3.4.24.35
Organism:Homo sapiens
Human
PDB IDs:-

Binding Affinities:

Ki: Kd:Ic 50:Ec50/Ic50:
----

References:

18571505
Inhibiting the platelet derived growth factor receptor increases signs of retinoic acid syndrome in myeloid differentiated HL-60 cells.. Gudrun Reiterer; Rodica P Bunaciu; James L Smith; Andrew Yen (2008) FEBS letters display abstract
PDGFR inhibitors are successfully used in a number of cancer treatments. The standard treatment for acute promyelocytic leukemia (APL) involves differentiation therapy with retinoic acid (RA). However, the relapse rates are significant. In the present work we evaluated the effects of RA therapy in the presence of PDGFR inhibitor, AG1296. Adding AG1296 with RA increased secretion of TNF-alpha, IL-8, and MMP-9 expression. This treatment induced higher levels of ICAM-1 endothelial cell expression, and increased cellular mobility. Inhibiting PDGFR enhanced RA-induced expression of integrin. Integrin ligand increased differentiation markers CD11b, inducible oxidative metabolism and PDGFR-beta phosphorylation. While the neutrophil-endothelial cell interactions are strengthened by the combined treatment, the endothelium-substratum interactions are weakened, a situation common in RAS.